-
Observational Study
Continuous renal replacement therapy in COVID-19-associated AKI: adding heparin to citrate to extend filter life-a retrospective cohort study.
- ValleEduardo de OliveiraEOHospital das Clínicas, University of São Paulo School of Medicine, Av. Dr. Arnaldo, 455, 3º andar, sala 3310, São Paulo, SP, CEP 01246-903, Brazil., Carla Paulina Sandoval Cabrera, AlbuquerqueClaudia Coimbra César deCCCHospital das Clínicas, University of São Paulo School of Medicine, Av. Dr. Arnaldo, 455, 3º andar, sala 3310, São Paulo, SP, CEP 01246-903, Brazil., Giovanio Vieira da Silva, OliveiraMárcia Fernanda Arantes deMFAHospital das Clínicas, University of São Paulo School of Medicine, Av. Dr. Arnaldo, 455, 3º andar, sala 3310, São Paulo, SP, CEP 01246-903, Brazil., Gabriel Teixeira Montezuma Sales, Igor Smolentzov, Bernardo Vergara Reichert, Lucia Andrade, SeabraVictor FariaVFHospital das Clínicas, University of São Paulo School of Medicine, Av. Dr. Arnaldo, 455, 3º andar, sala 3310, São Paulo, SP, CEP 01246-903, Brazil., Paulo Ricardo Gessolo Lins, and Camila Eleuterio Rodrigues.
- Hospital das Clínicas, University of São Paulo School of Medicine, Av. Dr. Arnaldo, 455, 3º andar, sala 3310, São Paulo, SP, CEP 01246-903, Brazil.
- Crit Care. 2021 Aug 19; 25 (1): 299299.
BackgroundCoronavirus disease 2019 (COVID-19) may predispose patients to thrombotic events. The best anticoagulation strategy for continuous renal replacement therapy (CRRT) in such patients is still under debate. The purpose of this study was to evaluate the impact that different anticoagulation protocols have on filter clotting risk.MethodsThis was a retrospective observational study comparing two different anticoagulation strategies (citrate only and citrate plus intravenous infusion of unfractionated heparin) in patients with acute kidney injury (AKI), associated or not with COVID-19 (COV + AKI and COV - AKI, respectively), who were submitted to CRRT. Filter clotting risks were compared among groups.ResultsBetween January 2019 and July 2020, 238 patients were evaluated: 188 in the COV + AKI group and 50 in the COV - AKI group. Filter clotting during the first filter use occurred in 111 patients (46.6%). Heparin use conferred protection against filter clotting (HR = 0.37, 95% CI 0.25-0.55), resulting in longer filter survival. Bleeding events and the need for blood transfusion were similar between the citrate only and citrate plus unfractionated heparin strategies. In-hospital mortality was higher among the COV + AKI patients than among the COV - AKI patients, although it was similar between the COV + AKI patients who received heparin and those who did not. Filter clotting was more common in patients with D-dimer levels above the median (5990 ng/ml). In the multivariate analysis, heparin was associated with a lower risk of filter clotting (HR = 0.28, 95% CI 0.18-0.43), whereas an elevated D-dimer level and high hemoglobin were found to be risk factors for circuit clotting. A diagnosis of COVID-19 was marginally associated with an increased risk of circuit clotting (HR = 2.15, 95% CI 0.99-4.68).ConclusionsIn COV + AKI patients, adding systemic heparin to standard regional citrate anticoagulation may prolong CRRT filter patency by reducing clotting risk with a low risk of complications.© 2021. The Author(s).
Notes
Knowledge, pearl, summary or comment to share?You can also include formatting, links, images and footnotes in your notes
- Simple formatting can be added to notes, such as
*italics*
,_underline_
or**bold**
. - Superscript can be denoted by
<sup>text</sup>
and subscript<sub>text</sub>
. - Numbered or bulleted lists can be created using either numbered lines
1. 2. 3.
, hyphens-
or asterisks*
. - Links can be included with:
[my link to pubmed](http://pubmed.com)
- Images can be included with:
![alt text](https://bestmedicaljournal.com/study_graph.jpg "Image Title Text")
- For footnotes use
[^1](This is a footnote.)
inline. - Or use an inline reference
[^1]
to refer to a longer footnote elseweher in the document[^1]: This is a long footnote.
.